Network meta-analysis of 42 trials (23,619 patients) found fixed-ratio combinations of basal insulin and GLP-1RA achieve comparable HbA1c control to free combinations, with significantly better outcomes for body weight and blood pressure.
23,619 patients across 42 trialsThe largest network meta-analysis comparing fixed-ratio vs. free combination insulin+GLP-1RA in T2DM, finding comparable HbA1c control but better weight/BP outcomes with free combinations
What the researchers found
Fixed-ratio combinations (IDegLira, iGlarLixi) and free combinations of basal insulin + GLP-1RA showed comparable HbA1c reduction (MD 0.07%, 95% CI -0.17 to 0.30), but free combinations produced significantly greater weight loss (-2.06 kg) and blood pressure reductions.
Why it matters
Many diabetes patients eventually need both insulin and a GLP-1 drug. This comprehensive analysis helps clinicians and patients choose between the convenience of a single-pen combination versus the potentially better metabolic outcomes of separate injections.
The numbers in context
Network meta-analysis included phase III clinical trials of IDegLira, iGlarLixi, and free combinations. Databases searched through April 2023.
How the study worked
Network meta-analysis following PROSPERO registration (CRD42023409585). Eight databases searched through April 2023. 42 Phase III clinical trials (23,619 patients) with uncontrolled T2DM included. Treatments categorized as FRC, free combination, or neither. Primary outcomes: HbA1c, body weight, hypoglycemia. Secondary: blood pressure.
Who was studied
Adults with uncontrolled type 2 diabetes mellitus
What this study cannot tell us
Network meta-analysis comparing across trials rather than within direct head-to-head studies. The weight and blood pressure differences, while statistically significant, are modest in clinical terms. Different trial designs, patient populations, and dose titration protocols may introduce heterogeneity. Cost and availability differences between FRC and free combinations not assessed.
How to read the evidence
Strong evidence from a large, well-conducted network meta-analysis of Phase III clinical trials with prospective registration and comprehensive database searches.
When this study was published
Published in 2024, covering trials through April 2023 — reflects the current evidence base for combination insulin+GLP-1RA therapy.
The bigger picture
Treatment simplification is a major goal in diabetes management — fewer injections typically means better adherence. This analysis shows that fixed-ratio pens achieve comparable blood sugar control with the convenience of a single injection, though at a modest cost in weight loss and blood pressure benefits. For many patients, the adherence benefits of simpler regimens may outweigh the metabolic trade-offs.
Questions still open
- Does the convenience of fixed-ratio combinations translate into better real-world adherence and outcomes?
- Could the weight advantage of free combinations be clinically meaningful for patients with obesity-driven diabetes?
- Will next-generation combination products narrow the weight loss gap while maintaining dosing simplicity?
Common questions
Should I use a combination pen or take my insulin and GLP-1 drug separately?
What are IDegLira and iGlarLixi?
Read the original research
Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
Journal of evidence-based medicine, 17(2), 370-376
Citation
Weng, Junling; Tao, Ying; Xu, Zian; Zhou, Shanyan; Xiao, Dunming; Zhu, Zhixu; Zheng, Ruizhi; Yang, Yi; Chen, Yingyao. (2024). Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.. Journal of evidence-based medicine, 17(2), 370-376. https://doi.org/10.1111/jebm.12620